The XBI is up 30% in six months, beating the S&P 500 by 24 percentage points — and the gap only widened in April.
Most patients “won’t see benefit” with Alzheimer’s drugs
A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.

